HQL-79

• CAT Number: I011407
• CAS Number: 162641-16-9
• Molecular Formula: C22H27N5O
• Molecular Weight: 377.492
• Purity: ≥95%
• Target: Synthases/Synthetases
• Solubility: Soluble in DMSO > 10 mM
• Storage: Store at RT
• IUPAC Name: 4-benzhydryloxy-1-[3-(2H-tetrazol-5-yl)propyl]piperidine
• InChI: InChI=1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26)
• InChIKey: TZQGXAHOROZEKN-UHFFFAOYSA-N
• SMILES: C1CN(CCC1OC(C2=CC=CC=C2)C3=CC=CC=C3)CCCC4=NNN=N4

HQL-79 (CAT: I011407) is indeed a selective inhibitor of hematopoietic prostaglandin D synthase (HPGDS). HPGDS is an enzyme involved in the synthesis of prostaglandin D2 (PGD2), which plays a role in various physiological and pathological processes, including inflammation and allergic responses. By inhibiting HPGDS, HQL-79 can modulate the production of PGD2 and potentially have anti-inflammatory and immunomodulatory effects. It has been studied for its potential therapeutic applications in inflammatory diseases such as asthma and allergic rhinitis.

Reference

1: Aritake K, Kado Y, Inoue T, Miyano M, Urade Y. Structural and functional
characterization of HQL-79, an orally selective inhibitor of human hematopoietic
prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281(22):15277-86. Epub 2006 Mar
17. PubMed PMID: 16547010.

2: Matsushita N, Aritake K, Takada A, Hizue M, Hayashi K, Mitsui K, Hayashi M,
Hirotsu I, Kimura Y, Tani T, Nakajima H. Pharmacological studies on the novel
antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and
antiasthmatic effects. Jpn J Pharmacol. 1998 Sep;78(1):11-22. PubMed PMID:
9804057.

3: Matsushita N, Hizue M, Aritake K, Hayashi K, Takada A, Mitsui K, Hayashi M,
Hirotsu I, Kimura Y, Tani T, Nakajima H. Pharmacological studies on the novel
antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various
experimental models. Jpn J Pharmacol. 1998 Sep;78(1):1-10. PubMed PMID: 9804056.